HTL Biotechnology solidifies its global leadership in pharmaceutical-grade biopolymer production and development by acquiring Modern Meadow’s beauty and biomedical division, headquartered in Nutley, NJ. This acquisition encompasses Modern Meadow’s portfolio of recombinant proteins, with the highlight being human recombinant collagen type III (rhCOL3).
HTL Biotechnology’s venture into recombinant human collagen for both cosmetic and medical applications represents a significant advancement, catering to the growing demand for Vegan-friendly options and offering unique and distinguishing properties.
The development of rhCOL3, originating in the United States and manufactured in Europe, has garnered considerable interest from various stakeholders in the cosmetic and aesthetic industries. This recombinant human collagen holds immense potential in an emerging market projected to exceed the billion-dollar threshold soon.
Through this acquisition, HTL Biotechnology aims to foster innovation across its traditional segments such as aesthetic medicine, rheumatology, and ophthalmology, while also exploring new therapeutic avenues. The synergy between HTL Biotechnology’s expertise in high-quality GMP biofermentation and this newly acquired platform of recombinant proteins will facilitate the creation of groundbreaking innovations, harnessing a blend of biopolymers and propelling the company’s innovative prowess forward.
HTL Biotechnology is expanding its product offerings with a diverse portfolio that includes pharmaceutical-grade hyaluronic acid, polynucleotides, and ongoing developments like heparosan and botulinum toxin as a neuromodulator. Moreover, the acquisition grants HTL Biotechnology access to a platform specializing in human recombinant collagens.
This move also signifies HTL Biotechnology’s strengthened presence in North America. This involves the integration of teams from HTL Biotechnology Manufacturing Inc. (HTL BMI) located in Massachusetts and the addition of the newly acquired organization headquartered in Nutley, New Jersey.
HTL Biotechnology, a French biotech company, holds a prominent position globally in the responsible development and manufacturing of pharmaceutical-grade biopolymers. These biopolymers serve as crucial components for healthcare companies, aiding in the creation of treatments across various key therapeutic fields such as ophthalmology, dermatology, medical aesthetics, and rheumatology.
Modern Meadow is a biotech company based in New York that has been dedicated to the development of bio-leather. The company secured Series A and Series B funding rounds in 2014 and 2016, respectively, with investors including Horizons Ventures, a venture capital firm under the Li Ka-shing Foundation. It’s reported that the company has accumulated total funding of $184 million to date.
